Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05935748
Other study ID # NKT2152-202
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 28, 2023
Est. completion date September 2026

Study information

Verified date December 2023
Source NiKang Therapeutics, Inc.
Contact Joanna Dojillo, M.Sc.
Phone 3024155127
Email clinicaltrials@nikangtx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.


Description:

This is a Phase 2 open-label, multicenter, global study of NKT2152. This study is designed as two phases: a Lead-in phase and an Expansion phase. Patients must be 18 years or older, with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Eligible patients must have progressed or relapsed after at least 1 prior anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) systemic therapy and 1 immune checkpoint inhibitor (ICI) for advanced or metastatic ccRCC alone or in combination. The Lead-in phase is designed as a dose escalation phase to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy. The subsequent Expansion phase will evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib and sasanlimab in advanced or metastatic ccRCC patients who received prior therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 172
Est. completion date September 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI. - Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) - KPS score of at least 70% - Able to swallow oral medications. Exclusion Criteria: - Active CNS metastases and/or carcinomatous meningitis - Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease - Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug. - Has known HIV - History of hepatitis B or known active hepatitis C infection - Has received prior treatment with NKT2152, other HIF2a inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab - Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment - Corrected QT interval calculated by Fridericia formula (QTcF) > 480 ms within 28 days prior to first dose - Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past - Has a history of interstitial lung disease - Has any active or recent history of a known or suspected autoimmune disease

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Advanced Renal Cell Carcinoma
  • Carcinoma
  • Carcinoma, Renal Cell
  • ccRCC
  • Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Diseases
  • Kidney Neoplasms
  • Metastatic Renal Cell Carcinoma
  • Neoplasm by Histology
  • Neoplasms
  • Neoplasms by Site
  • Neoplasms, Glandular and Epithelial
  • Recurrent Renal Cell Carcinoma
  • Refractory Renal Cell Carcinoma
  • Renal Cancer
  • Renal Neoplasms
  • Urogenital Neoplasms
  • Urologic Diseases
  • Urologic Neoplasms

Intervention

Drug:
NKT2152
Oral HIF2a inhibitor
palbociclib
a cyclin-dependent kinases (CDK) 4 and 6 inhibitor
Other:
sasanlimab
an immunoglobulin G4 (IgG4) monoclonal antibody that blocks PD-1; a solution for injection for subcutaneous administration

Locations

Country Name City State
United States University of Michigan-Rogel Cancer Center Ann Arbor Michigan
United States Dana-Farber Cancer Institute Boston Massachusetts
United States University of Virginia Health System Charlottesville Virginia
United States Northwestern University - Feinberg School of Medicine Chicago Illinois
United States UT Southwestern Medical Center Dallas Texas
United States University of California San Diego La Jolla California
United States Memorial Sloan Kettering Cancer Center New York New York
United States Nebraska Cancer Specialists Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
NiKang Therapeutics, Inc. Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Dose Limiting Toxicity (DLT) events during the DLT monitoring period (first 28 days of dosing) in the Lead-in Phase DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0. 28 days
Primary Objective Response Rate (ORR) determined by the Investigator ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 1 years
Secondary Progression-free survival (PFS) PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death. 2 years
Secondary Duration of Response (DOR) Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first. 1 years
Secondary Time to Response (TTR) TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed. 1 years
Secondary Overall Survival (OS) OS defined as the time from the date the participant started study drug to death for any reason. 2 years
Secondary Clinical Benefit Rate (CBR) CBR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) or a stable disease (SD) of 8 weeks or longer based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 1 years
Secondary Number of Participants with Adverse Events An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. 2 years
Secondary Maximum observed plasma concentration (Cmax) of NKT2152 Maximum observed plasma concentration (Cmax) of NKT2152 1 years
Secondary Time to maximum observed plasma concentration of NKT2152 (Tmax) Time to maximum observed plasma concentration of NKT2152 (Tmax) 1 years
Secondary Observed trough concentration of NKT2152 (Ctrough) Observed trough concentration of NKT2152 (Ctrough) 1 years
Secondary Area under the plasma concentration time curve (AUC0-t) of NKT2152, and accumulation ratio (RAC) Area under the plasma concentration time curve (AUC0-t) of NKT2152, and accumulation ratio (RAC) 1 years
Secondary Maximum observed plasma concentration (Cmax) of palbociclib Maximum observed plasma concentration (Cmax) of palbociclib 1 years
Secondary Time to maximum observed plasma concentration of palbociclib (Tmax) Time to maximum observed plasma concentration of palbociclib (Tmax) 1 years
Secondary Observed trough concentration of palbociclib (Ctrough) Observed trough concentration of palbociclib (Ctrough) 1 years
Secondary Area under the plasma concentration time curve (AUC0-t) of palbociclib, and accumulation ratio (RAC) Area under the plasma concentration time curve (AUC0-t) of palbociclib, and accumulation ratio (RAC) 1 years
Secondary Observed trough concentration of sasanlimab (Ctrough) Observed trough concentration of sasanlimab (Ctrough) 1 years
Secondary Maximum observed plasma concentration (Cmax) of sasanlimab Maximum observed plasma concentration (Cmax) of sasanlimab 1 years
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2